Infliximab
Brand Names: Renflexis, Remicade
Methodology & AI Transparency ⓘ
Infliximab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage renflexis: is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
- 2 Real-world patient consensus: Zero-PHI community consensus: 74% favorable across 5 logged regimens (Renflexis, Remicade).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Infliximab): headache (10.9%), abdominal discomfort (5.1%), nasopharyngitis (5.4%).
Ask our AI Specialists anything about Infliximab
Infliximab Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage renflexis: is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.
12.1 Mechanism of Action Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab products do not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα.
Pharmacokinetic profiling of Infliximab demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–16 hour t½ intervals for Infliximab with Complete (~100%) parenteral systemic delivery for Infliximab (100 mg/10mL Injection, Powder, Lyophilized, for Solution) systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar infliximab conjugates, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after infliximab administration.
Titration schedules for Infliximab (100 mg/10mL Injection, Powder, Lyophilized, for Solution → 100 mg/1 Injection, Powder, Lyophilized, for Solution) require excluding the use of renflexis at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure .; contraindicated in patients with prior serious allergic response to infliximab (ndc 78206-162); real-world patient logs highlight headache (10.9% of reports), nausea (8.5% of reports), dizziness (6.7% of reports) alongside a 74.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Infliximab in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Infliximab maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- The use of RENFLEXIS at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure .
- Contraindicated in patients with prior serious allergic response to Infliximab (NDC 78206-162)
Logged Side-Effect Incidence (5 Reports)
Infliximab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Infliximab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Although ileal disease is often more treatment resistant, IFX SC maintenance therapy was effective vs PBO regardless of disease location, demonstrating consistent efficacy across segments including the terminal ileum. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2026-04-15 • Phase III Randomized Trial | N = 173 | 88/100 | PMID 41285264 ↗ |
| Can This Approach Help? Inside the Latest Research on Gut Microbial Species and Endotypes Associate with full symptom relief in In this large study of ulcerative colitis patients, we show that few individual species associate strongly with clinical full symptom relief, but multivariate models including microbiome can predict clinical full symptom... Journal of Crohn's & colitis • 2024-11-04 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38836628 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of subcutaneous vs intravenous infliximab in autoimmune joint pain IFX s.c. Rheumatology (Oxford, England) • 2023-08-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36534825 ↗ |
| Can This Approach Help? Inside the Latest Research on Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Here we describe increased serum glucose levels as a novel independent predictor of baseline infliximab clearance. Journal of clinical pharmacology • 2021-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 32905628 ↗ |
Infliximab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1135.9660/unit (~$34078.98/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Infliximab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Infliximab RxNorm Concept ID | 1927285 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1135.9660 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Infliximab Patient Community, Cohort Filters & Dosage Logs
Deterministic Infliximab reference combining NIH RxNorm (1927285), Medicaid NADAC ($1135.9660/unit), and anonymous cohort outcomes (74% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Infliximab community threads and patient logs by age, biological sex, dosage, and treatment duration.